Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China-Biotics continues probiotics growth

This article was originally published in The Tan Sheet

Executive Summary

New retail products sold in the firm's Shining outlets helped drive net sales up 35.5 percent to $15.4 million in the first quarter of fiscal 2010. Shanghai-based China-Biotics reported Aug. 17 that net income for the April-June also rose significantly, to $5.8 million from $3.2 million. Quarterly earnings per share grew to 34 cents from 19 cents, the firm said. Looking ahead, the probiotics manufacturer intends to slow retail expansion as it readies a new facility to begin trial production of bulk additives in its second quarter (1"The Tan Sheet" July 20, 2009). China-Biotics added it applied in July for patents for four probiotics-based yogurt products with China's State Intellectual Property Office and anticipates receiving patent certificates in about two years
Advertisement

Related Content

Sales & Earnings In Brief
Sales & Earnings In Brief

Topics

Advertisement
UsernamePublicRestriction

Register

PS103247

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel